BioCryst Pharmaceuticals
BCRX
8.40
+0.45
+5.66%
BioCryst Pharmaceuticals
US · BCRX
#2766 by market cap
Listed 1970
8.40
+0.45
+5.66%
Live - 5344 symbols - heartbeat 131s ago
· 2026-10-08 08:27
Pre-market
8.48
+0.91%
After-hours
8.38
-0.24%
- Market cap
- 2.15B
- P/E (TTM)i
- -6.00
- P/Bi
- -4.72
- EPSi
- 1.21
- Div yieldi
- 0.00%
- 52W posi
- 46%
Reader sentiment
Are you bullish or bearish on BCRX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 3 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.5 percentage points.
Institutional ownership
- Held by institutions
- 103.79% -0.47pp
- Institutions
- 376 -3
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund54.54%
Hedge Fund22.21%
VC/PE Fund17.01%
Public Company4.30%
Private Company3.61%
Government Pension Fund1.15%
Individual/Insider0.90%
Insurance Company0.75%
Family Office/Trust0.16%
Top holders as of 2026-06-30
BlackRock
9.35% · 23.89M sh
RA Capital Management, L.P.
6.19% · 15.83M sh
State Street Global Advisors
5.94% · 15.19M sh
Deerfield Management Company, L.P.
5.91% · 15.10M sh
Vanguard Capital Management, LLC
5.14% · 13.12M sh
Vanguard Portfolio Management, LLC
4.36% · 11.14M sh
TCG Crossover Management, LLC
4.31% · 11.02M sh
Perceptive Advisors LLC
4.03% · 10.31M sh
Janus Henderson Group plc
3.73% · 9.54M sh
Vestal Point Capital, LP
3.25% · 8.30M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 38 buys · 9 sells
| Name | Role | Stake |
|---|---|---|
| Jon Stonehouse | Chief Executive Officer | 0.41% |
| Charles Gayer | Chief Commercial Officer | 0.14% |
| Anthony Doyle | Senior Vice President | 0.08% |
| Helen Thackray | Chief Research & Development Officer | 0.06% |
| Alane Barnes | Chief Legal Officer | 0.06% |
| Vincent Milano | Independent Director | 0.04% |
| Steven K. Galson | Independent Director | 0.02% |
| Theresa Heggie | Independent Director | 0.02% |
| Alan Levin | Independent Director | 0.02% |
| Ronald Dullinger | Chief Commercial Officer | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-30 | Vincent Milano | Independent Director | Other Acquisition | +1,159 | $9.70 |
| 2026-08-30 | Steve Frank | Director | Other Acquisition | +1,288 | $9.70 |
| 2026-08-30 | Jill Milne | Director | Other Acquisition | +1,288 | $9.70 |
| 2026-08-30 | Jon Stonehouse | Chief Executive Officer | Other Acquisition | +644 | $9.70 |
| 2026-08-30 | Amy McKee | Independent Director | Other Acquisition | +644 | $9.70 |
| 2026-06-10 | Vincent Milano | Independent Director | Other Acquisition | +15,294 | -- |
| 2026-06-10 | Vincent Milano | Independent Director | Other Derivative Acquisition | +33,540 | $8.50 |
| 2026-06-10 | Alan Levin | Independent Director | Other Acquisition | +15,294 | -- |
| 2026-06-10 | Alan Levin | Independent Director | Other Derivative Acquisition | +33,540 | $8.50 |
| 2026-06-10 | Steve Frank | Director | Other Acquisition | +15,294 | -- |
| 2026-06-10 | Steve Frank | Director | Other Derivative Acquisition | +33,540 | $8.50 |
| 2026-06-10 | Jill Milne | Director | Other Acquisition | +15,294 | -- |
| 2026-06-10 | Jill Milne | Director | Other Derivative Acquisition | +33,540 | $8.50 |
| 2026-06-10 | Theresa Heggie | Independent Director | Other Acquisition | +15,294 | -- |
| 2026-06-10 | Theresa Heggie | Independent Director | Other Derivative Acquisition | +33,540 | $8.50 |
| 2026-06-10 | Jon Stonehouse | Chief Executive Officer | Other Acquisition | +15,294 | -- |
| 2026-06-10 | Jon Stonehouse | Chief Executive Officer | Other Derivative Acquisition | +33,540 | $8.50 |
| 2026-06-10 | Steven K. Galson | Independent Director | Other Acquisition | +15,294 | -- |
| 2026-06-10 | Steven K. Galson | Independent Director | Other Derivative Acquisition | +33,540 | $8.50 |
| 2026-06-10 | A. Sanders | Independent Director | Other Acquisition | +15,294 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:27:26 · For reference only, not investment advice and not tailored to your situation.